92
Participants
Start Date
March 7, 2025
Primary Completion Date
November 30, 2025
Study Completion Date
January 31, 2026
KPC000154 10mg Tablet Intervention
KPC000154 10mg Tablet administered orally in the morning once daily for 1 day
KPC000154 30mg Tablet Intervention
KPC000154 30mg Tablet administered orally in the morning once daily for 1 day
KPC000154 60mg Tablet Intervention
KPC000154 60mg Tablet administered orally in the morning once daily for 1 day
KPC000154 120mg Tablet Intervention
KPC000154 120mg Tablet administered orally in the morning once daily for 1 day
KPC000154 200mg Tablet Intervention
KPC000154 200mg Tablet administered orally in the morning once daily for 1 day
KPC000154 300mg Tablet Intervention
KPC000154 300mg Tablet administered orally in the morning once daily for 1 day
KPC000154 400mg Tablet Intervention
KPC000154 400mg Tablet administered orally in the morning once daily for 1 day
KPC000154 80mg multiple-dose Tablet Intervention（To Be Determined）
KPC000154 80mg tablet administered orally in the morning for 14 days
KPC000154 120mg multiple-dose Tablet Intervention（To Be Determined）
KPC000154 80mg tablet administered orally in the morning for 14 days
KPC000154 40mg multiple-dose Tablet Intervention（To Be Determined）
KPC000154 120mg tablet administered orally in the morning for 14 days
Placebo-controlled（SAD）
A placebo used in a single-dose study where participants receive either the experimental drug or the placebo.
Placebo-controlled（MAD）
A placebo used in a multiple-dose study where participants receive either the experimental drug or the placebo.
No.49, Huayuan North Road, Haidian District, Beijing City, Beijing
Lead Sponsor
Kunming Pharmaceuticals, Inc.
INDUSTRY